ME02810B - Antigen-specifični t ćelijski receptori i t ćelijski epitopi - Google Patents

Antigen-specifični t ćelijski receptori i t ćelijski epitopi

Info

Publication number
ME02810B
ME02810B MEP-2017-163A MEP16317A ME02810B ME 02810 B ME02810 B ME 02810B ME P16317 A MEP16317 A ME P16317A ME 02810 B ME02810 B ME 02810B
Authority
ME
Montenegro
Prior art keywords
cell
antigen
nucleic acid
reactive
providing
Prior art date
Application number
MEP-2017-163A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ugur Sahin
Özlem Türeci
Petra Simon
Tana Omokoko
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of ME02810B publication Critical patent/ME02810B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (4)

1. Postupak za obezbeđivanje antigen-specifičnih limfoidnih ćelija koji sadrži korake:(a) obezbeđivanja T ćelije reaktivne na jedan antigen iz uzorka koji sadrži T ćelije, pri čemu je navedeni uzorak dobijen od subjekta koji je prethodno izložen navedenom antigenu i pri čemu je navedena T ćelija reaktivna na jedan antigen izolovana iz uzorka koji sadrži T ćelije upotrebom protočne citometrije;(b) obezbedivanja nukleinske kiseline koja kodira T ćelijski receptor koji ima specifičnost T ćelijskog receptora navedene T ćelije reaktivne na jedan antigen; i(e) uvođenja navedene nukleinske kiseline u limfoidnu ćeliju da bi se obezbedile navedene antigen-specifične limfoidne ćelije.
2. Postupak prema patentnom zahtjevu 1, naznačen time što je navedena nukleinska kiselina RNK.
3. Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što navedeni korak obezbeđivanja nukleinske kiseline koja kodira T ćelijski receptor koji ima specifičnost T ćelijskog receptora navedene T ćelije reaktivne na jedan antigen sadrži obezbeđivanje nukleinske kiseline koja kodira T ćelijski receptor koji sadrži najmanje CDR sekvence, poželjno najmanje varijabilni region T ćelijskog receptora navedene T ćelije reaktivne na jedan antigen.
4. Postupak prema bilo kom od patentnih zahtjeva 1 do 3, naznačen time što je navedeni subjekat seropozitivan za navedeni antigen ili agens koji sadrži navedeni antigen.
MEP-2017-163A 2010-09-20 2011-09-19 Antigen-specifični t ćelijski receptori i t ćelijski epitopi ME02810B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10009990 2010-09-20
EP11000045 2011-01-05
EP11761508.8A EP2618835B1 (en) 2010-09-20 2011-09-19 Antigen-specific t cell receptors and t cell epitopes
PCT/EP2011/004674 WO2012038055A1 (en) 2010-09-20 2011-09-19 Antigen-specific t cell receptors and t cell epitopes

Publications (1)

Publication Number Publication Date
ME02810B true ME02810B (me) 2018-01-20

Family

ID=45873461

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-163A ME02810B (me) 2010-09-20 2011-09-19 Antigen-specifični t ćelijski receptori i t ćelijski epitopi

Country Status (20)

Country Link
US (4) US9586997B2 (me)
EP (3) EP2618835B1 (me)
JP (5) JP6378485B2 (me)
CN (4) CN110951690A (me)
AU (4) AU2011304728A1 (me)
BR (2) BR112013006718B1 (me)
CA (3) CA3088393C (me)
CY (1) CY1119332T1 (me)
DK (1) DK2618835T3 (me)
ES (1) ES2635335T3 (me)
HK (1) HK1243003A1 (me)
HR (1) HRP20171164T1 (me)
LT (1) LT2618835T (me)
ME (1) ME02810B (me)
PL (1) PL2618835T3 (me)
PT (1) PT2618835T (me)
RS (1) RS56339B1 (me)
SI (1) SI2618835T1 (me)
SM (1) SMT201700393T1 (me)
WO (1) WO2012038055A1 (me)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2387627T3 (en) 2009-01-15 2016-07-04 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for producing monoclonal antibodies
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
CN104507963B (zh) 2012-05-22 2017-12-15 美国卫生和人力服务部 鼠抗‑ny‑eso‑1 t细胞受体
EP3636665B1 (en) * 2012-09-14 2022-06-29 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing mhc class ii-restricted mage-a3
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
AU2013357239B2 (en) 2012-12-14 2019-10-17 Biontech Rna Pharmaceuticals Gmbh Novel MHC-independent tumor-associated antigens
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
WO2015058780A1 (en) * 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
KR102415259B1 (ko) 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
US10370427B2 (en) 2013-12-19 2019-08-06 Friedrich-Alexander Universität Erlangen-Nürnberg Influenza-specific T-cell receptor and its uses in the detection, prevention and/or treatment of influenza
JP6508873B2 (ja) * 2014-01-20 2019-05-08 国立大学法人富山大学 抗原特異的ｔ細胞受容体の取得方法
CA2941612A1 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
ES2777529T3 (es) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
CA2956545A1 (en) * 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
ES2784343T3 (es) 2014-10-29 2020-09-24 Adaptive Biotechnologies Corp Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
SG11201703309PA (en) * 2014-10-31 2017-05-30 Baylor College Medicine Survivin specific t-cell receptor targeting tumor but not t cells
CN107206024B (zh) 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
EP3215165B1 (en) * 2014-11-05 2020-12-23 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
EP3233903B1 (en) 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
EP3237374A4 (en) 2014-12-23 2018-04-25 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
EP3259284B1 (en) 2015-02-16 2020-04-01 The Trustees of the University of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
EP3591074B1 (en) * 2015-02-24 2024-10-23 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
ES2790725T3 (es) 2015-03-16 2020-10-29 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Procedimiento de detección de nuevos epítopos de células T inmunogénicas y aislamiento de nuevos receptores de células T específicas de antígeno mediante una biblioteca de células de MHC
EP3273975A4 (en) * 2015-03-26 2018-10-17 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
ES2842849T3 (es) * 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2017048593A1 (en) * 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
US10928392B2 (en) 2015-09-25 2021-02-23 Abvitro Llc High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
CN108290940B (zh) * 2015-10-01 2021-12-07 圣拉斐尔医院有限公司 Tcr及其用途
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3383427A4 (en) * 2015-12-04 2019-11-27 Mayo Foundation for Medical Education and Research METHOD AND VACCINES FOR INDUCTION OF IMMUNE REACTIONS TO SEVERAL DIFFERENT MHC MOLECULES
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP3399985B1 (en) * 2016-01-06 2022-02-23 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
JP7161404B2 (ja) 2016-02-26 2022-10-26 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
CR20220248A (es) 2016-03-16 2022-07-18 Immatics Biotechnologies Gmbh Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
RS63727B1 (sr) 2016-03-16 2022-12-30 Immatics Biotechnologies Gmbh Transficirane t ćelije i t-ćelijski receptori za upotrebu u imunoterapiji protiv malignih tumora
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
JP7240176B2 (ja) 2016-04-08 2023-03-15 アダプティミューン・リミテッド Ｔ細胞受容体
BR112018070600A2 (pt) 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
BR112018070637A2 (pt) 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP7046016B2 (ja) * 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
CA3032870A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3538113A4 (en) * 2016-11-14 2020-08-19 Fred Hutchinson Cancer Research Center HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
CN108117596B (zh) 2016-11-29 2023-08-29 香雪生命科学技术（广东）有限公司 针对ny-eso的高亲和力tcr
EP3568412A2 (en) 2017-01-13 2019-11-20 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
EP3354658A1 (en) * 2017-01-25 2018-08-01 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
EP3601594A4 (en) * 2017-03-24 2021-04-14 The Board of Trustees of the Leland Stanford Junior University ANTIGEN DETECTION FOR T-CELL RECEPTORS ISOLATED FROM PATIENT TUMORS THAT DETECT WILD TYPE ANTIGENS AND POTENT PEPTIDE MIMOTOPES
CN110662760A (zh) * 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
US11352389B2 (en) * 2017-06-30 2022-06-07 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
US20220305102A1 (en) * 2017-06-30 2022-09-29 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
CN107630005A (zh) * 2017-09-19 2018-01-26 深圳市北科生物科技有限公司 表达plac1特异性tcr的t细胞及其应用
CN107557339A (zh) * 2017-09-19 2018-01-09 深圳市北科生物科技有限公司 特异性识别plac1的t细胞及其与细胞因子的联合的应用
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
KR102905054B1 (ko) 2017-11-22 2025-12-29 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
CN119770648A (zh) 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CA3097399A1 (en) 2018-04-19 2019-10-24 The Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
CN110857319B (zh) * 2018-08-24 2023-12-08 杭州康万达医药科技有限公司 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
AU2019339332A1 (en) * 2018-09-10 2021-04-08 Torque Therapeutics, Inc. Antigen-specific T lymphocytes and methods of making and using the same
BR112021003996A2 (pt) * 2018-09-12 2021-05-25 Universität Basel receptores de célula t restritos à mr1 para imunoterapia contra o câncer
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
KR20210112310A (ko) * 2018-12-06 2021-09-14 광동 티씨알큐어 바이오파마 테크놀로지 씨오., 엘티디. 종양 항원, tgf-베타 및 면역체크포인트를 표적으로 하는 tcr-t 세포 복합 치료법
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
MX2021010542A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
KR20210149050A (ko) * 2019-03-04 2021-12-08 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
WO2020178741A1 (en) 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
CN113853434A (zh) * 2019-03-04 2021-12-28 大学健康网络 T细胞受体及其使用方法
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021022447A1 (zh) * 2019-08-05 2021-02-11 广东香雪精准医疗技术有限公司 识别afp抗原短肽的t细胞受体
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
EP4048293A4 (en) 2019-10-21 2023-12-06 Flaskworks, LLC Systems and methods for cell culturing
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
WO2021142081A1 (en) * 2020-01-07 2021-07-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using induced pluripotent stem cells
CN111234004B (zh) * 2020-02-28 2023-03-28 陕西九州新药评价研究有限公司(西安新药评价研究中心) 识别wt1抗原短肽的t细胞受体及其应用
US20230405046A1 (en) * 2020-03-16 2023-12-21 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
CN113667008A (zh) * 2020-05-15 2021-11-19 香雪生命科学技术（广东）有限公司 一种识别afp抗原的高亲和力t细胞受体
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2022015922A1 (en) * 2020-07-16 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
CN114106144B (zh) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 识别hla-a*02/wt1靶点的tcr及其应用
EP4237433A4 (en) * 2020-10-27 2024-10-09 T-Cure Bioscience, Inc. RECOMBINANT T CELL RECEPTORS THAT BIND CANCER ANTIGENS NY-ESO-1 AND/OR LAGE-1A
US20230399402A1 (en) * 2020-11-03 2023-12-14 La Jolla Institute For Immunology Hla class ii-restricted tcrs against the kras g12>v activating mutation
AU2022256469A1 (en) * 2021-04-14 2023-10-12 Academisch Ziekenhuis Leiden Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
AU2022283277A1 (en) * 2021-05-25 2023-12-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
CN115171787A (zh) * 2022-07-08 2022-10-11 腾讯科技（深圳）有限公司 抗原预测方法、装置、设备以及存储介质
WO2024054863A1 (en) * 2022-09-06 2024-03-14 Board Of Regents, The University Of Texas System T-cell receptor that targets egfr mutation and methods of using the same
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
WO2024148181A2 (en) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer
US20240303488A1 (en) * 2023-03-09 2024-09-12 Immunitybio, Inc. Method and system for t-cell receptor (tcr) assay design
WO2025010229A2 (en) * 2023-07-06 2025-01-09 Board Of Regents, The University Of Texas System T-cell receptors targeting foxm1 and methods of use thereof
WO2025085216A1 (en) * 2023-10-19 2025-04-24 The Brigham And Women's Hospital, Inc. T-switch: a specificity-based engineering platform for developing safe and effective t cell therapeutics
WO2025101584A1 (en) * 2023-11-06 2025-05-15 Immunitybio, Inc. Virally educated t cells
CN121319150A (zh) * 2025-12-16 2026-01-13 温州医科大学 一种同时识别hbv核心抗原表位及包膜蛋白表位的tcr及其编码序列

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
ES2279585T3 (es) 1997-09-23 2007-08-16 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
JP4776852B2 (ja) * 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ
US20020107388A1 (en) * 2000-05-12 2002-08-08 Vandenbark Arthur A. Methods of identifying and monitoring disease-associated T cells
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
DE10109854A1 (de) * 2001-03-01 2002-09-12 Thomas Stanislawski Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MXPA06001739A (es) 2003-08-14 2006-05-12 Asahi Kasei Pharma Corp Derivado de acido arilalcanoico substituido y uso del mismo.
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1758935B1 (en) * 2004-05-26 2009-04-29 Immunocore Ltd. High affinity telomerase t cell receptors
CA2575604A1 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
WO2006026002A2 (en) * 2004-08-03 2006-03-09 New York University T cell receptors with enhanced sensitivity recognition of antigen
US7915036B2 (en) * 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP5079697B2 (ja) * 2005-08-05 2012-11-21 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US7820174B2 (en) * 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
JP5292550B2 (ja) 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US20110030074A1 (en) * 2007-05-21 2011-02-03 Dana Farber Cancer Institute, Inc. Compositions and methods for cancer gene discovery
US7928190B2 (en) * 2007-07-05 2011-04-19 Darnell Robert B Methods and compositions for tumor vaccination and therapy
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法
JP2009278927A (ja) * 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
US20100011199A1 (en) 2008-07-09 2010-01-14 Au Group Electronics Method and device of bootloader-to-go
WO2010105298A1 (en) 2009-03-18 2010-09-23 Simon Barry Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof

Also Published As

Publication number Publication date
EP3590530A1 (en) 2020-01-08
US11311611B2 (en) 2022-04-26
AU2016206329A1 (en) 2016-08-18
EP3213765A2 (en) 2017-09-06
BR112013006718A2 (pt) 2016-11-01
BR112013006718B1 (pt) 2021-12-07
WO2012038055A1 (en) 2012-03-29
DK2618835T3 (en) 2017-08-28
JP2016136939A (ja) 2016-08-04
US10117918B2 (en) 2018-11-06
PT2618835T (pt) 2017-08-08
AU2011304728A1 (en) 2013-03-14
JP6735893B2 (ja) 2020-08-05
AU2019202864A1 (en) 2019-05-16
CY1119332T1 (el) 2018-04-04
EP3590530B1 (en) 2021-12-29
HRP20171164T1 (hr) 2017-10-20
CN105255834A (zh) 2016-01-20
JP6625705B2 (ja) 2019-12-25
JP2013541332A (ja) 2013-11-14
US20190060430A1 (en) 2019-02-28
CA3088393A1 (en) 2012-03-29
AU2019202864B2 (en) 2020-03-19
CA2812153C (en) 2020-06-30
CN103249430A (zh) 2013-08-14
US20130273647A1 (en) 2013-10-17
CA3071740C (en) 2020-09-08
BR112013006718A8 (pt) 2017-09-19
JP2020202833A (ja) 2020-12-24
PL2618835T3 (pl) 2017-12-29
EP3213765A3 (en) 2017-09-20
SI2618835T1 (sl) 2017-10-30
SMT201700393T1 (it) 2017-09-07
CN117756916A (zh) 2024-03-26
JP2019004902A (ja) 2019-01-17
CN105255834B (zh) 2019-11-12
BR122020026648B1 (pt) 2021-12-07
EP3213765B1 (en) 2019-08-28
US9586997B2 (en) 2017-03-07
JP2020048570A (ja) 2020-04-02
CN110951690A (zh) 2020-04-03
JP6400613B2 (ja) 2018-10-03
CA3088393C (en) 2021-08-17
RS56339B1 (sr) 2017-12-29
JP6378485B2 (ja) 2018-08-22
HK1243003A1 (en) 2018-07-06
ES2635335T3 (es) 2017-10-03
US20170112911A1 (en) 2017-04-27
CA3071740A1 (en) 2012-03-29
JP7012788B2 (ja) 2022-02-14
CA2812153A1 (en) 2012-03-29
AU2016206329B2 (en) 2017-12-14
AU2018201252A1 (en) 2018-03-15
EP2618835A1 (en) 2013-07-31
AU2018201252B2 (en) 2019-02-28
US20220288180A1 (en) 2022-09-15
LT2618835T (lt) 2017-10-10
EP2618835B1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
ME02810B (me) Antigen-specifični t ćelijski receptori i t ćelijski epitopi
HRP20201185T1 (hr) Gdf zamke
Jansson et al. MicroRNA and cancer
Chappert et al. Human anti-smallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and long-lasting germinal center imprinting
GB2513793A (en) Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
WO2006050138A3 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
FI20116256A7 (fi) Menetelmä ja järjestely kiinteän oksidin kennon toimintaolosuhteiden ilmaisemiseksi
DK2121920T3 (da) Fremgangsmåde til kloning af sammenhørende antistoffer
MX2014007262A (es) Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
JP2015504661A5 (me)
HRP20251544T1 (hr) Monoklonsko protutijelo protiv interleukina-31
HRP20220107T1 (hr) Proteini koji vežu kalikrein plazme
HRP20191895T1 (hr) Adam6 miševi
NZ611600A (en) Means and methods for producing high affinity antibodies
HRP20161548T1 (hr) Protutijela za il-25
MY200303A (en) Kinetic exclusion amplification of nucleic acid libraries
MX367170B (es) Enriquecimiento de la clasificacion de las celulas activadas por fluorescencia (facs) para generar plantas.
JP2009531023A5 (me)
PH12013501412A1 (en) Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
IN2014CN02113A (me)
CN102212888A (zh) 一种基于高通量测序的免疫组库构建方法
EP2536430A4 (en) COMPOSITIONS AND METHODS FOR TARGETING TYPE 1 INTERFERON PRODUCING CELLS
EP3821226A1 (en) Microfluidic devices and methods of use
MX2013014475A (es) COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.
Agudelo et al. Role of Extracellular Vesicles in Severe Dengue: Virus–Host Interactions and Biomarker Potential